An 8.0 mm flat-faced bevel-edged tablet core containing 45.0 wt% bone collagen peptide API, 42.5 wt% microcrystalline cellulose (Ph. Eur. 4.1.1), 6.0 wt% crospovidone, 3.5 wt% croscarmellose sodium, 1.5 wt% magnesium stearate, and 0.5 wt% colloidal silicon dioxide is dry-blended for 18 min at 10 rpm in a 600 L bin blender. Production-scale compression on a 20-station rotary press with 8.0 mm round tooling and turret speed of 25–35 rpm has demonstrated that direct compression remains stable only when the incoming peptide fraction is pre-sieved to D₉₀ ≤ 180 µm and conditioned at 20–25 °C, ≤ 40% RH. If the peptide fraction exceeds 65 wt% of the core weight, tablet tensile strength falls below 1.5 MPa and upper punch sticking becomes recurrent above 55% RH. Blend uniformity is assessed before lubrication at 10 sampling points, with acceptance of ≤ 5.0% RSD for peptide content. Compression force is held at 8–15 kN to maintain tablet hardness between 8–12 kp, friability below 1.0%, and disintegration below 15 min. Release testing for this oral solid dosage form is anchored to USP <905> Uniformity of Dosage Units, USP <701> Disintegration, USP <711> Dissolution in 0.1 N HCl at 37 ± 0.5 °C, and elemental impurity control under ICH Q3D(R2) 2022. Aqueous film coating is performed with a 12% w/w HPMC-based suspension at pan speed 6–10 rpm, inlet air 55–65 °C, exhaust air 40–45 °C, and coating weight gain of 3–4 wt%. The downstream process sequence comprises sieving, bin blending, lubricant addition, compression, film coating, and packaging in PVC-PVDC blisters. Finished product types emerging from this route are film-coated immediate-release tablets containing 250–500 mg peptide per unit, used in adult bone support and mobility formulations where standard oral disintegration and dissolution profiles are required.

Does Capsule Plug Cohesion Fail When Peptide Bulk Density Drops Below 0.38 g/mL?

For hard shell capsule filling, a dry-blended composition containing 55.0 wt% bone collagen peptide, 28.0 wt% dibasic calcium phosphate dihydrate, 10.0 wt% microcrystalline cellulose, 4.0 wt% sodium starch glycolate, 2.0 wt% colloidal silicon dioxide, and 1.0 wt% sodium stearyl fumarate is filled into size 0 hard gelatin or HPMC capsules using an intermittent dosator machine running at 12,000–20,000 capsules/h. The principal process limit is plug cohesion: when the peptide bulk density is below 0.38 g/mL, dosator pins lift non-uniform plugs and capsule weight variation exceeds 4.0% RSD, particularly after the powder bed drops below 30% of its initial height. At peptide loadings above 70 wt%, the blend becomes cohesive under ambient moisture and may require a pregranulation step rather than direct encapsulation. In contrast, a tamping-pin capsule filler with 2–3 tamping stations can accommodate slightly lower bulk densities if pin height is reduced and the powder bed is maintained above 50% of the hopper volume. Regulatory conformance is established through USP <905>, USP <701>, USP <711>, and dissolution testing in 0.1 N HCl for immediate-release gelatin capsules or pH 6.8 phosphate buffer for HPMC capsules; animal-origin compliance follows EMA/410/01 Rev.3 and Ph. Eur. 5.2.8 TSE provisions. The downstream production sequence is low-shear tumble mixing at 10–15 rpm, delumping through an 800 µm screen, capsule filling, weight sorting, and packaging in HDPE bottles or cold-form foil blisters. Finished forms produced are 350–550 mg hard capsules containing 192–385 mg of peptide, intended for once- or twice-daily oral regimens where capsule-specific disintegration and lower excipient load are desired.

When Moisture Uptake Exceeds 12% w/w, Granulation Binder Concentration Must Be Rebalanced

Fluid-bed top-spray granulation is selected for high-dose oral powder delivery because the peptide fraction has poor flow and high hygroscopicity. A formulation with 70.0 wt% bone collagen peptide, 15.0 wt% mannitol, 5.0 wt% povidone K30, 4.0 wt% citric acid, 3.0 wt% maltodextrin, 1.5 wt% croscarmellose sodium, 0.5 wt% silicon dioxide, and 1.0 wt% flavor is granulated in a 300 L top-spray fluid bed. The binder solution is 10% w/w povidone K30 in purified water, sprayed at 6–8 g/min/kg with inlet air at 65–70 °C, product temperature held at 34–38 °C, and atomizing air at 1.5–2.0 bar. Drying continues to a loss-on-drying endpoint below 3.0%. If the dried granule moisture uptake exceeds 12% w/w during subsequent exposure at 55% RH for 60 min, the binder concentration must be increased to 6.0 wt% relative to dry solids, because low-binder films around peptide particles hydrate and lose interparticle bridges, resulting in stick-pack clogging and dissolution lag. Mannitol is used instead of lactose to limit Maillard browning at inlet air temperatures above 65 °C. The target granule size distribution is D₅₀ 250–450 µm with fines below 150 µm not exceeding 15%, because excessive fines reduce sachet fill weight precision. Compendial release follows USP <905>, USP <701>, USP <711> in 900 mL water at 37 ± 0.5 °C with paddle speed 50 rpm, and elemental impurity limits of ICH Q3D(R2) 2022; TSE documentation is maintained under EMA/410/01 Rev.3 for bovine-derived input. Downstream processing comprises sifting of the milled granulate through an 800 µm sieve, dosing into single-dose stick packs at 2.5 g or 5.0 g peptide per pack, and hermetic sealing in polyester-aluminum-polyethylene laminate within 30 min of dryer discharge. Finished categories are oral powder sachets and stick packs for clinical nutrition, dysphagia-modified diets, and adult bone support protocols requiring high peptide payloads without tablet swallowing difficulty.

An injectable preparation using bone collagen peptide API is compounded as a sterile aqueous solution containing 1.0–3.0% w/v peptide, 0.9% w/v sodium chloride, 5–20 mM phosphate buffer, and 0.1–0.5% w/v polysorbate 80 where aggregation control is required. Dissolution is performed in Water for Injection at 20–25 °C under low-shear overhead stirring at 100–200 rpm for 30–45 min; the pH is adjusted with 0.1 M hydrochloric acid or 0.1 M sodium hydroxide to 4.5–6.5. The solution is prefiltered through a 0.45 µm polyethersulfone capsule and then sterile-filtered through a 0.22 µm PES membrane at a constant flux of 8–15 L/m²/h; membrane fouling is observed when high-molecular-weight aggregate content exceeds 2.0% of total peptide area by size-exclusion chromatography. The injectable process requires aseptic filling in an ISO 14644-1 Class 5 environment under EU GMP Annex 1, with terminal sterilization not routinely applicable because of heat-induced peptide aggregation. Compliance is demonstrated through USP <1> Injections, USP <85> Bacterial Endotoxins at a limit derived from 0.25 EU/mg or dose-based calculation, USP <788> Particulate Matter in Injections, USP <790> Visible Particulates, 21 CFR 210/211, and ICH Q3D(R2) 2022 for elemental impurities. The terminal finished formats are 5 mL or 10 mL Type I glass vials, ampoules, or prefilled syringes. Published clinical or compendial data for injectable bone collagen peptide formulations remain limited; each dossier therefore requires product-specific validation of sterility, aggregation, and subvisible particle behavior before commercial release.

Lyophilized Cake Collapse Temperature, Residual Moisture, and Reconstitution Time

Injectable lyophilized formulations require a matrix that stabilizes the peptide during freezing and sublimation. A representative frozen solution contains 5.0% w/v bone collagen peptide, 3.0% w/v mannitol, 10 mM phosphate buffer, and 0.05% w/v polysorbate 80 at pH 6.0. The solution is filled into 5 mL Type I glass vials with a fill volume of 2.0–2.5 mL, then frozen at 0.5 °C/min to -40 °C and held for 4 h. Primary drying is conducted at a shelf temperature of -20 °C to -10 °C and a chamber pressure of 150–250 µbar for 18–24 h; the target product temperature remains below the collapse temperature, which must be confirmed by freeze-drying microscopy because collagen peptide formulations can exhibit collapse events below -18 °C depending on salt load. Secondary drying at 25–35 °C for 8–12 h reduces residual moisture to below 3.0% w/w as determined by USP <921> Water Determination. Release testing includes USP <1>, USP <85>, USP <788>, USP <790>, and container closure integrity per USP <1207>. The finished format is a sterile lyophilized cake in Type I glass vials closed with chlorobutyl stoppers, reconstituted with 2.5 mL Water for Injection to a nominal 5.0% peptide solution. Published data for this specific configuration are limited; therefore cake appearance, reconstitution time, and subvisible particle counts are product-specific acceptance criteria rather than compendial fixed limits.

High-Dose Wet Granulation Reverses Die-Fill Variability Above 70 wt% Peptide Loading

When a tablet core must exceed 70 wt% bone collagen peptide, dry mixing alone cannot maintain acceptable die-fill precision; the switch to high-shear wet granulation reduces tablet weight variation from above 5.0% RSD to below 2.5% RSD on a 45-station rotary press running at 35–45 rpm. A production batch uses 75.0 wt% peptide, 10.0 wt% microcrystalline cellulose, 4.0 wt% povidone K90, 4.0 wt% croscarmellose sodium, 2.0 wt% pregelatinized starch, 1.5 wt% magnesium stearate, and 1.0 wt% talc. Granulation is performed in a 600 L high-shear mixer: dry mixing for 5 min, addition of a 5.0% w/w povidone K90 solution at 2–4 kg/min, impeller speed 300 rpm, chopper speed 1500 rpm, wet massing to a 15–20% motor current rise, wet milling through a 6.0 mm screen, fluid-bed drying at 60–65 °C inlet air to LOD < 3.0%, and dry milling through a 1.0 mm screen. Release criteria are assessed under USP <905>, USP <701>, USP <711> in 0.1 N HCl, and impurity controls under ICH Q3D(R2) 2022; if the peptide source is bovine, EMA/410/01 Rev.3 and Ph. Eur. 5.2.8 documentation accompanies the batch record. The finished formats are high-dose immediate-release tablets at 600–800 mg core weight with 3–4 wt% aqueous film coating, used when a single tablet must deliver 500 mg or more peptide without exceeding acceptable swallowability constraints.